ReFlow Therapeutics is Awarded Swiss Public CTI Grant

ReFlow Therapeutics is Awarded Swiss Public CTI Grant

Baar, Switzerland, January 30th 2017

ReFlow Therapeutics AG (“ReFlow”) today announced that the Company has been awarded a Swiss non-dilutive public grant from the Swiss Commission for Technology and Innovation (CTI). CTI is promoting Swiss start-ups during applied research projects which are carried out in cooperation with leading Swiss universities. The total grant is CHF 823,925 (converts to USD 824,000) and runs over 18 months.

The project named “Development and non-clinical verification of a diagnostic and therapeutic approach to treat microvascular obstructions in heart attack patients” is a cooperation with Prof. Dominik Obrist (University of Bern, ARTORG Center of Biomedical Engineering Research, Cardiovascular Engineering), Prof. Urs Moser (NTB Interstate University of Applied Sciences Buchs), Prof. Sebastian Kozerke (University and ETH Zurich, Inst. for Biomedical Engineering) and Nikola Cesarovic (University Hospital Zürich, Division of Surgical Research).

Prof. Obrist, who is heading the project, said: “We are excited to start the cooperation with ReFlow to better understand microvascular obstructions in the coronary circulation. The interdisciplinary research consortium brings together unique capabilities in magnetic resonance imaging (MRI), non-clinical research and circulatory modelling which will be instrumental to gain new insights into the coronary microcirculation”.

“The CTI project will enable us to develop solid MRI protocols and non-clinical models to document the value of the ReFlow Controlled Flow Infusion (CoFITM) technology. We are very pleased to work with leading Swiss scientists to document the benefit of our arterial technology to diagnose and treat microvascular obstructions”, said Jon H. Hoem, ReFlow’s CEO and Co-Founder.

ReFlow is currently developing the CoFITM console and rapid exchange (RX) catheter for non-clinical trials to generate data for its regulatory design dossiers. The Company targets to complete these development stages over the next 18 months and will provide regular updates on the progress of the Company.

In some severe heart attack patients (STEMI), the whole left ventricular wall is not perfused (“no-reflow”) as shown on the MRI image above. However, thrombus formed in these patients is porous and can be dissolved. Microvascular obstructions (MVO) and “no-reflow” are created by thrombus and other effects which reduce the blood flow in the coronary micro-circulation. The ReFlow Controlled Flow Infusion (CoFITM) technology seeks to diagnostically determine the root cause of MVO and then treat the tissue accordingly. In patients where the micro-channels are blocked by thrombus, it can be dissolved by using intracoronary infusion of different approved drugs such as anti-thrombotic agents. The ReFlow CoFITM system will enable the wash-out of the thrombi and a real-time monitoring of the microvascular status. Based on the improved myocardial microcirculation, the therapy will be adjusted while the patient is still in the cathlab. The ReFlow CoFITM technology will not interfere with the normal workflow for severe heart attack patients nor require additional skills by the interventional cardiologists.

Share this post

Leave a Reply

Your email address will not be published. Required fields are marked *

2 × three =